Dyslipidaemia and psychiatric patients [3]

Canadian Journal of Psychiatry

Volumn 49, Issue 12, 2004, Pages 864-

  Menzies, Robin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; C REACTIVE PROTEIN; GLUCOSE; LIPID; STATINE DERIVATIVE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; LIPID BLOOD LEVEL; MENTAL PATIENT; PATIENT MONITORING; PREDICTION; PRIMARY MEDICAL CARE; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

CHOLESTEROL; HUMANS; HYPERLIPIDEMIAS; MENTAL DISORDERS; PROTEIN C;

EID: 12744253719     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, and others. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 2003;48:689-94.
2. Gianfrancesco F, White R, Wang RH, Nasrallah AH. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2003;64:847-8.
3. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes and lipid abnormalities. Can J Psychiatry 2001;46:273-81.
4. Health Canada. The growing burden of heart disease and stroke in Canada. Ottawa: Health Canada, May 2003.
5. Ridker PM, Rifai N, Buring JE, Cook NR. Comparisons of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med 2002;347:1557-65.
6. Boilson M, Hamilton RJ. A survey of monitoring of weight and blood glucose in in-patients. Psychiatr Bull 2003;27:424-6.
7. Archie S, Wilson JH, Osborne S, Hobbs H, McNiven J. Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. Can J Psychiatry 2003;48:628-32.